New imaging study could reveal why some lung cancers respond better to targeted therapy

NCT ID NCT07436858

First seen Mar 12, 2026 · Last updated May 20, 2026 · Updated 10 times

Summary

This study will use a special PET scan to track a drug called trastuzumab in the bodies of 20 people with advanced lung cancer that has changes in the HER2 protein. The goal is to see if the drug builds up differently in tumors with a HER2 mutation compared to those with too much HER2 protein. This is an early-phase study that does not provide treatment but aims to improve future therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Netherlands Cancer Institute - Antoni van Leeuwenhoek

    Amsterdam, North Holland, 1066CX, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.